F. Liu et al., Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors, P NAS US, 98(20), 2001, pp. 11062-11068
Citations number
47
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Cyclin-dependent kinase 5 (Cdk5) is a multifunctional neuronal protein kina
se that is required for neurite outgrowth and cortical lamination and that
plays an important role in dopaminergic signaling in the neostriatum throug
h phosphorylation of Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosph
oprotein, molecular mass 32 kDa). Casein kinase 1 (CK1) has been implicated
in a variety of cellular functions such as DNA repair, circadian rhythm, a
nd intracellular trafficking. In the neostriatum, CK1 has been found to pho
sphorylate Ser-137 of DARPP-32. However, first messengers for the regulatio
n of Cdk5 or CK1 have remained unknown. Here we report that both Cdk5 and C
K1 are regulated by metabotropic glutamate receptors (mGluRs) in neostriata
l neurons. (S)3,5-dihydroxyphenylglycine (DHPG), an agonist for group I mGl
uRs, increased Cdk5 and CK1 activities in neostriatal slices, leading to th
e enhanced phosphorylation of Thr-75 and Ser-137 of DARPP-32, respectively.
The effect of DHPG on Thr-75, but not on Ser-137, was blocked by a Cdk5-sp
ecific inhibitor, butyrolactone. In contrast, the effects of DHPG on both T
hr-75 and Ser-137 were blocked by CK1-7 and IC261, specific inhibitors of C
K1, suggesting that activation of Cdk5 by mGluRs requires CK1 activity. In
support of this possibility, the DHPG-induced increase in Cdk5 activity, me
asured in extracts of neostriatal slices, was abolished by CK1-7 and IC261.
Treatment of acutely dissociated neurons with DHPG enhanced voltage-depend
ent Ca2+ currents. This enhancement was eliminated by either butyrolactone
or CK1-7 and was absent in DARPP-32 knockout mice. Together these results i
ndicate that a CK1-Cdk5-DARPP-32 cascade may be involved in the regulation
by mGluR agonists of Ca2+ channels.